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Background
The prognostic value of cytogenetic findings in chronic myelomonocytic leukemia is unclear.
Our purpose was to evaluate the independent prognostic impact of cytogenetic abnormalities
in a large series of patients with chronic myelomonocytic leukemia included in the database of
the Spanish Registry of Myelodysplastic Syndromes.
Design and Methods
We studied 414 patients with chronic myelomonocytic leukemia according to WHO criteria
and with a successful conventional cytogenetic analysis at diagnosis. Different patient and dis-
ease characteristics were examined by univariate and multivariate methods to establish their
relationship with overall survival and evolution to acute myeloid leukemia.
Results
Patients with abnormal karyotype (110 patients, 27%) had poorer overall survival (P=0.001)
and higher risk of acute myeloid leukemia evolution (P=0.010). Based on outcome analysis,
three cytogenetic risk categories were identified: low risk (normal karyotype or loss of Y chro-
mosome as a single anomaly), high risk (presence of trisomy 8 or abnormalities of chromosome
7, or complex karyotype), and intermediate risk (all other abnormalities). Overall survival at
five years for patients in the low, intermediate, and high risk cytogenetic categories was 35%,
26%, and 4%, respectively (P<0.001). Multivariate analysis confirmed that this new CMML-
specific cytogenetic risk stratification was an independent prognostic variable for overall sur-
vival (P=0.001). Additionally, patients belonging to the high-risk cytogenetic category also had
a higher risk of acute myeloid leukemia evolution on univariate (P=0.001) but not multivariate
analysis.
Conclusions
Cytogenetic findings have a strong prognostic impact in patients with chronic myelomonocytic
leukemia.
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Introduction 
Chronic myelomonocytic leukemia (CMML) is a rare
clonal hematologic disorder, with a heterogeneous clinical
and morphological expression, sharing features of both
myelodysplastic syndromes (MDS) and chronic myelopro-
liferative disorders. Classification of chronic myelomono-
cytic leukemia is controversial. It was considered a
myelodysplastic syndrome disorder in the original FAB
(French–American–British) classification.1 In 1994, the FAB
group distinguished two subtypes of chronic myelomono-
cytic leukemia depending on the absolute leukocyte count
at diagnosis (lower and equal or greater than 13×109/L):2 a
myelodysplastic syndrome type (CMML–MD) and a
myeloproliferative disorder variant (CMML–MP). Taking
this into account, chronic myelomonocytic leukemia cases
with an absolute leukocyte count greater than 12×109/L
were excluded from the cooperative study that resulted in
the development of the International Prognostic Scoring
System (IPSS).3 More recently, the World Health
Organization’s (WHO) panel of experts decided to include
chronic myelomonocytic leukemia in a new category of
mixed myeloproliferative/myelodysplastic neoplasms and
to segregate chronic myelomonocytic leukemia cases into
two categories, CMML-1 and CMML-2, depending on the
proportion of blasts in peripheral blood (PB) and bone mar-
row (BM).4,5
Certain chromosomal abnormalities have a strong
impact on the outcome for patients with myelodysplastic
syndrome and are used for risk stratification in both the
IPSS and the WHO classification-based prognostic scoring
system (WPSS).3,6 However, the prognostic value of chro-
mosomal abnormalities in chronic myelomonocytic
leukemia is unclear. The only series assessing the potential
impact of cytogenetics in chronic myelomonocytic
leukemia was unable to find an independent relationship
between cytogenetic results and outcomes.7
The aims of this study were to evaluate the incidence
and independent prognostic value of cytogenetic abnor-
malities in a large series of 414 patients from the Spanish
MDS Registry diagnosed with chronic myelomonocytic
leukemia and with a successful conventional cytogenetic
study available.
Design and Methods
Data collection
The Spanish MDS Registry is a database of the Spanish MDS
cooperative group, which was constituted in 2005 to promote col-
laborative research among Spanish institutions working on
myelodysplastic syndromes. The database includes retrospective
and prospective clinical and biological data from patients diag-
nosed with myelodysplastic syndromes at the participating insti-
tutions. On completion of this report the database contained com-
plete information on 564 patients with chronic myelomonocytic
leukemia. All data were verified and updated by the institution's
physicians and data managers, and double-checked for avoiding
duplicate cases.
Patients
A total of 414 patients diagnosed with chronic myelomonocytic
leukemia between 1980 and 2008, with a successful conventional
cytogenetic analysis at diagnosis, and included in the database of
the Spanish MDS Registry constitute the basis of the present
report (participating institutions are listed in Appendix 1).
Diagnosis of chronic myelomonocytic leukemia was made
according to WHO criteria.4,5 In keeping with the guidelines of the
Declaration of Helsinki, this retrospective non-interventional
study was conducted with the approval of both the internal
review board of Bioethics and Medical Research at the University
Hospital La Fe and the Spanish MDS Registry. All patients or legal
guardians provided informed consent.
Cytogenetics
Bone marrow samples for cytogenetic analysis were obtained
from all patients at the time of diagnosis and were processed
after short-term culture (24 h) following standard procedures.
The chromosomes were stained by G-banding and cytogenetic
results were interpreted and reported according to the
International System for Human Cytogenetic Nomenclature
(ISCN, 2005)8 recommendations. The presence of less than 20
evaluable metaphases did not disqualify cases from study inclu-
sion as long as 10 or more metaphases were examined in those
patients with normal karyotypes. Most cytogenetic analyses
were performed at nine reference laboratories participating in an
external quality program of the Spanish Haematological
Cytogenetics Working Group (Grupo Cooperativo Español de
Citogenética Hematológica, GCECGH). The cytogenetic reports
but not the original metaphase slides from all cases were
reviewed centrally (JC and ES) to ensure they followed the ISCN
2005 nomenclature guidelines.8
Prognostic factors
Different patient and disease characteristics, recorded at the
time of diagnosis, were examined in the prognostic factor analysis
to establish their possible relationship with overall survival (OS)
and evolution to acute myeloid leukemia (AML). These include
basic demographic data (age and sex), year of diagnosis, hemato-
logic parameters (hemoglobin level, leukocyte count, polymor-
phonuclear cell (PMN) count, absolute platelet count, presence of
blasts in peripheral blood), proportion of blasts in bone marrow,
LDH level, and cytogenetics. For cytogenetic prognostic catego-
rization, chromosomal abnormalities were classified into six dif-
ferent cytogenetic categories: normal karyotype, trisomy 8 (alone
or with one additional abnormality), isolated loss of Y chromo-
some, complex karyotype (three or more abnormalities), anom-
alies of chromosome 7 (monosomy 7 or del(7q) alone or with one
additional abnormality) and other miscellaneous abnormalities
(other single or double chromosomal abnormalities). The IPSS
cytogenetic risk classification was also considered.3 All character-
istics were analyzed as dichotomous variables and the cut-off
points selected for each one were those presented in Table 1.
March 2002 was the date that divided the series in 2 groups with
the same number of patients and was selected as cut-off point to
evaluate a potential influence in the results of changes in the prac-
tical management of chronic myelomonocytic leukemia patients
over time and exclude its possible association with other relevant
prognostic variables.  
Statistical analysis
The χ2 and Fisher’s exact tests were used to analyze differences
in the distribution of variables among patient subsets.
Unadjusted time-to-event analyses were performed using the
Kaplan-Meier estimate and log rank tests were used for compar-
isons. Multivariate analysis was performed using Cox’s propor-
tional hazards regression model. Characteristics selected for pos-
sible inclusion in the multivariate model were those for which
there was some indication of association with overall survival or
acute myeloid leukemia evolution in univariate analysis (P<0.20).
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Table 1. Clinical and hematologic characteristics of patients with CMML related to survival and risk of AML evolution.
Overall survival AML evolution
Characteristic N. of Median Proportion P Time to 25% Cumulative P
patients (%) (mo) alive probability probability
at 5 yr (%) (mo) of AML evolution (%)
At 2 yr At 5 yr
Overall 414 (100) 35 33 39 15 29
Year of diagnosis 0.91 0.894
Before March 2002 205 (50) 30 69 61 15 29
After March 2002 209 (50) 29 76 65 15 24
Age, year 0.03 0.142
< 70 146 (35) 40 40 58 20 33
≥ 70 268 (65) 31 30 66 12 25
Gender 0.08 0.090
Male 287 (69) 29 30 35 15 35
Female 127 (31) 42 40 66 15 17
Secondary 0.19 0.539
No 377 (91) 49 34 57 13 26
Yes 37 (9) 36 20 34 5 25
WHO classification < 0.001 < 0.001
CMML-1 367 (89) 37 35 66 11 25
CMML-2 47 (11) 8 .08 10 53 62
Hemoglobin level, g/dL < 0.001 0.004
< 10 147 (36) 14 15 25 23 36
≥ 10 265 (64) 47 41 59 11 24
Leukocyte count, ×109/L < 0.001 < 0.001
< 13 248 (60) 48 43 66 12 20
≥ 13 166 (40) 18 17 26 20 48
Platelet count, ×109/L < 0.001 0.387
< 100 157 (38) 23 29 28 21 32
≥ 100 257 (62) 36 34 57 11 26
PMN count, ×109/L 0.242 0.619
< 1.8 82 (20) 42 29 30 17 28
≥ 1.8 332 (80) 29 35 38 14 28
Blasts in PB < 0.001 < 0.001
Absent 312 (90) 42 38 58 11 24
Present 34 (10) 15 0 12 38 54
Proportion of blasts in BM, % < 0.001 < 0.001
0 to 9 364 (92) 36 35 57 11 25
10 to 19 44 (8) 7 1 10 60 70
LDH, U/L < 0.001 0.567
≤ 480 270 (68) 39 37 66 10 20
> 480 128 (32) 19 7 28 10 24
Karyotype 0.001 0.010
Normal 304 (73) 39 36 59 12 27
Abnormal 110 (27) 16 23 13 26 36
Cytogenetic categories < 0.001 0.001
Normal karyotype 304 (73) 39 36 59 12 27
Trisomy 8 alone or with one additional 30 (7.2) 11 13 12 41 41
abnormality
Isolated loss of Y chromosome 18 (4.3) 41 41 25 11 26
Complex karyotype (≥3 abnormalities) 12 (2.9) 9 0 7 44 NR
Abnormalities of chromosome 7 6 (1.5) 18 0 6 33 33
Miscellaneous (other single or double 44 (33) 19 27 8 21 34
abnormalities)
IPSS cytogenetic risk classification 0.001 0.005
Low-risk (isolated del(5q), del(20q), 327 (79) 37 36 59 12 27
and -Y and normal karyotype)
Intermediate-risk (all other  abnormalities) 67 (16) 12 20 12 29 38
High-risk (complex and abnormalities 20 (5) 11 12 7 46 46
of chromosome 7)
CMML-specific cytogenetic risk classification < 0.001 0.001
Low-risk  (normal karyotype and -Y) 324 37 35 59 12 27
Intermediate-risk  (all other  abnormalities) 39 18 26 10 20 33
High-risk (+8, abnormalities of chromosome 7 51 11 4 8 42 42
and complex karyotype)
NR: not reached; BM: bone marrow; PB: peripheral blood and IPSS: International Prognostic Scoring System.
The forward stepwise procedure was stopped when the P value
for entering an additional variable was above 0.05. Overall sur-
vival was measured from the time of diagnosis to the time of last
follow up or death from any cause. Evolution to acute myeloid
leukemia was measured from the time of diagnosis to the date of
acute myeloid leukemia evolution (presence of more than 19% of
blasts in bone marrow or peripheral blood). All patients received
supportive care [red blood cell (RBC) and platelet transfusions,
and antibiotics as required]. One hundred and seventy-three
patients with transfusion-dependent anemia received erythroid
stimulating agents and 65 received hydroxyurea to ameliorate
hyperleukocytosis and/or symptoms related to splenomegaly.
None of the patients had received azacitidine or decitabine.
Patients undergoing hematopoietic allogeneic stem cell transplan-
tation (n=4) or intensive AML-type chemotherapy (n=23) were
considered censored data at the date of transplant or the date of
starting chemotherapy. Patient follow up was updated on 15
January  2009, and all follow-up data were censored at that point.
The statistical package SPSS, version 17.0 (SPSS Inc., Chicago, IL,
USA) was used for all analyses. A two-sided P value below 0.05
was considered significant.
Results
Incidence and characteristics of chromosomal
abnormalities
Main patients’ characteristics are shown in Table 1. The
series included 287 (69%) males and 127 females (31%).
Median age was 72 years (range 17-99). According to FAB
criteria,2 248 patients (60%) had CMML-MD and 166
(40%) had CMML-MP. Morphological subtypes accord-
ing to the WHO classification were CMML-1 in 367
(89%) and CMML-2 in 47 (11%). Karyotype was normal
in 304 patients (73%) and abnormal in 110 (27%). The
most frequent cytogenetic abnormalities were trisomy 8
(n=30; isolated in 24 patients and with one additional
abnormality in 6: del(5)(q31q33), +10, del(11)(q14),
del(12)(p13),   add(17)(p13.3), +19, and +21, respectively),
isolated loss of Y chromosome (n=18), abnormalities of
chromosome 7 (n=6; isolated in 4 patients and with one
additional abnormality in 2; monosomy 7 in 5 and del(7q)
in one), and complex karyotype (n=12). Other miscella-
neous abnormalities were present in 44 patients.
Abnormalities present in at least 3 patients were del(20q)
(n=3; isolated in all instances), and del(5q) (n=3; isolated
in 2 patients and with one additional abnormality in one).
Other chromosomal abnormalities present in less than 3
patients were evident in 38 patients. More detailed infor-
mation on the different chromosomal abnormalities
encountered is available in Online Supplementary Figure S1.
There were significant differences in the proportion of
blasts in bone marrow, presence of blasts in peripheral
blood, and consequently in WHO subgroup, and presence
of dyserythropoiesis and dysgranulopoiesis between
patients with normal and abnormal karyotypes (Table 2).
Chromosomal abnormalities were more frequently found
in patients with CMML-2 subtype (P<0.001), 10% or
more blasts in bone marrow (P<0.001), presence of blasts
in peripheral blood (P<0.001), dyserythropoiesis
(P=0.015), and dysgranulopoiesis (P=0.037). There were
no differences in the frequency and pattern of chromoso-
mal abnormalities over time.
Prognostic value of cytogenetic findings
With a median follow up of 22 months for surviving
patients (range 1-157 months) the median survival was 35
months. Patients with normal karyotype had significantly
better survival than patients with abnormal karyotype
(P=0.001) and patients with isolated loss of Y chromo-
some also showed significantly longer survival than all
the remaining patients with abnormal karyotype
(P=0.020). By contrast, patients with trisomy 8 or com-
plex karyotypes had a shorter survival than all the other
patients (P<0.001 and P<0.001, respectively). Survival of
E. Such et al.
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Figure 1. Unadjusted
probability of overall
survival according to (A)
the new CMML-specific
and (B) the IPSS cytoge-
netic risk classifica-
tions.
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patients with miscellaneous chromosomal abnormalities
was significantly shorter than in patients with normal
karyotype or isolated loss of Y chromosome (P=0.017)
and also significantly longer than in patients with trisomy
8 or complex karyotype (P=0.007). No significant differ-
ences in survival were observed for any of the low-fre-
quency single or double aberrations included in the group
with miscellaneous abnormalities. The median survival of
patients with anomalies of chromosome 7 was 18
months, shorter than that observed in the overall series of
414 patients (35 months). But there were no statistically
significant differences in survival between this group of
patients and any of the other cytogenetic groups of
patients. It should be stressed that the outcome analyses
of low-frequency chromosomal aberrations, including
those of chromosome 7, were hampered by small sample
size.
Fifty-nine patients developed acute myeloid leukemia,
the median time to 25% probability of AML evolution
was 59 months, and the cumulative probability of AML
evolution at two and five years in the overall series of
patients was 15% and 29%, respectively. Presentation of
a complex karyotype was associated with a higher prob-
ability of developing acute myeloid leukemia (P<0.001)
and patients with trisomy 8 also showed a trend towards
a higher AML risk (P=0.081). In contrast, patients with
normal cytogenetics present a lower probability of AML
development (P=0.010). The median time to 25% proba-
bility of AML evolution of patients with abnormalities of
chromosome 7 was six months and the cumulative prob-
ability of AML evolution at two years was 33% but,
again, no statistically significant differences in AML evo-
lution risk between these patients and those in the
remaining cytogenetic groups were seen.
The prognostic impact of other clinical and hematolog-
ic characteristics on overall survival and risk of AML evo-
lution in univariate analysis is shown in Table 1.
Development of a new CMML-specific cytogenetic
risk classification
Taking into account the results observed in univariate
analyses we developed a new CMML-specific cytogenetic
risk classification. Patients were separated into three prog-
nostic subgroups related to their cytogenetic pattern: low,
intermediate, and high risk. Patients with normal kary-
otype and isolated loss of Y chromosome were assigned to
the low risk category. Patients with trisomy 8, chromo-
some 7 abnormalities, and complex karyotype were con-
sidered as high risk. The assignment of patients with
abnormalities of chromosome 7 to the high risk category
despite the lack of statistical significance in univariate
analysis was based on their particularly short overall sur-
vival and high risk of acute myeloid leukemia in the cur-
rent series and in other reported studies of patients with
chronic myelomonocytic leukemia,7 and in the IPSS
cohort.3 The remaining patients with any other single or
double abnormality were defined as intermediate risk.
The proportion of patients surviving at five years in these
three different cytogenetic risk categories was 35% for
low risk, 26% for intermediate risk, and 4% for high risk
(P < 0.001). The actuarial median survival of patients with-
in these three cytogenetic subgroups was 37, 18, and 11
months, respectively (Table 1 and Figure 1A). The new
CMML-specific cytogenetic risk classification was com-
pared with the IPSS cytogenetic risk classification which,
in contrast, includes normal karyotype, and isolated loss of
Y chromosome, del(5q) or del(20q) in the low risk group,
complex karyotype (three or more abnormalities),  or
chromosome 7 abnormalities in the high risk group, and
all other karyotypic abnormalities in the intermediate risk
group. The IPSS cytogenetic risk classification also
Cytogenetics in CMML
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Table 2. Comparative analysis of the characteristics of patients with
CMML according to the presence or absence of chromosomal abnor-
malities.
Characteristic Normal Abnormal P
karyotype karyotype
N. (%) N. (%)
Overall 304 (78) 110 (22)
Year of diagnosis 0.360
Before March 2002 148 (49) 59 (54)
After March 2002 156 (51) 51 (46)
Age, years 0.300
< 70 102 (34) 44 (40)
≥ 70 202 (66) 66 (60)
Gender 0.181
Male 205 (67) 82 (74)
Female 99 (43) 28 (36)
Secondary 0.247
No 279 (92) 90 (88)
Yes 25 (8) 12 (11)
WHO classification < 0.001
CMML-1 283 (93) 82 (75)
CMML-2 21 (7) 27 (25)
Hemoglobin, g/dL 0.101
< 10 101 (67) 46 (42)
≥ 10 203 (33) 64 (78)
Leukocyte count, ×109/L 0.102
< 13 187 (62) 60 (55)
≥ 13 117 (48) 50 (45)
Platelet count, ×109/L 0.283
< 100 113 (37) 43 (39)
≥ 100 189 (73) 64 (61)
PMN count, ×109/L 0.252
≤1.8 62 (20) 17 (16)
> 1.8 242 (80) 92 (84)
Blasts in PB < 0.001
Absent 245 (81) 67 (61)
Present 17 (19) 17 (39)
LDH, U/L 0.053
≤ 480 149 (70) 39 (58)
> 480 63 (30) 28 (42)
Proportion of blasts in BM, % < 0.001
0 to 9 292 (96) 91 (83)
10 to 19 12 (4) 19 (17)
Dysgranulopoiesis, % 0.037
≤ 10 27 (24) 4 (10)
> 10 88 (76) 36 (90)
Dyserythropoiesis, % 0.015
≤ 10 65 (59) 14 (37)
> 10 45 (41) 24 (63)
Dysthrombopoiesis, % 0.643
≤ 10 65 (50) 19 (45)
> 10 66 (50) 23 (55)
BM: bone marrow; PB: peripheral blood and IPSS, International Prognostic Scoring
System. 
showed a statistically significant association with survival
on univariate analysis (P=0.001), but was only capable of
segregating two risk groups, survival probabilities being
very similar for patients in the intermediate and high risk
categories (median survival 37, 12, and 11 months for
patients in the low, intermediate and high risk categories;
Figure 1B). There was a significant relationship between
the new CMML-specific cytogenetic risk classification
defined above and probability of AML evolution (overall
P=0.001, Figure 2A). The actuarial risk of AML evolution
at two years was 40% for patients in the high risk group,
20% for patients in the intermediate risk group, and 12%
for patients in the low risk group. Patients in the low risk
group had a statistically significantly lower risk of AML
evolution than patients in the intermediate group
(P=0.047). In contrast, no clear differences in risk of AML
evolution were evident between patients in the intermedi-
ate and high risk categories (P=NS). As shown in Figure
2B, the IPSS cytogenetic risk classification yielded similar
results. This system was significantly associated with
rates of AML evolution (overall P=0.005) but there was no
clear difference in risk of AML evolution for patients
between the intermediate and high risk categories (P=NS). 
Both the IPSS and the new CMML-specific cytogenetic
risk classifications were also significantly associated with
overall survival and AML evolution when the analyses
were restricted to patients with less or more than 12×109
leukocytes/L (Online Supplementary Table S1). However,
none of them was able to clearly segregate three risk
groups for overall survival or AML risk in patients with
CMML-MD or with CMML-MP. While the shape of the
survival curves with the new CMML-specific cytogenetic
risk classification in patients with CMML-MP was as
expected that was not the case with the IPSS cytogenetic
risk classification, where the survival curve for patients in
the intermediate risk category was below the survival
curve for patients in the high risk category (Online
Supplementary Figure S2).
Multivariate analysis confirmed that the new CMML-
specific cytogenetic risk classification had a strong and
independent prognostic impact on overall survival
(P<0.001) but not on AML evolution. The IPSS cytogenetic
risk categorization did not demonstrate a statistically sig-
nificant value once the new CMML-specific cytogenetic
risk classification was entered into the overall survival
regression model (P=0.076 when forced to enter the
regression model) and did not show an independent
impact on AML evolution risk. The main results of multi-
variate analyses of prognostic factors for both overall sur-
vival and AML evolution are shown in Table 3. 
E. Such et al.
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Table 3. Results of the multivariate analysis of survival and risk of AML evolution.
Overall Survival AML transformation
Characteristic and cut-off point Step of Wald statistic HR (95% CI) P value Step of Wald statistics HR (95% CI) P value
entry at entry entry at entry
Blasts in bone marrow ≥ 10% 1 51.99 1.82 (1.57-2.12) < 0.001
Leukocyte count ≥ 13×109/L 2 49.78 2.59 (2.02-3.37) < 0.001 1 8.63 2.93 (2.09-4.15) < .001
Hemoglobin level < 10 g/dL 3 25.13 1.48 (1.33-1.66) < 0.001 -- --
CMML-specific cytogenetic risk 4 23.92 1.70 (1.98-1.48) <0.001 -- --
classification, risk category 
Platelet count < 100×109/L 5 9.47 2.12(1.50-2.98) < 0.001 -- --
Figure 2. Unadjusted risk of AML evolution according to (A) the new
CMML-specific and (B) the IPSS cytogenetic risk classifications.
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Discussion
The present study shows, for the first time, that cytoge-
netic findings have a clear and independent relationship
with overall survival and, to a lesser extent, with the risk
of acute leukemic evolution in patients with chronic
myelomonocytic leukemia. 
Based on the survival analysis, we were able to define
three cytogenetic risk categories, low risk (normal kary-
otype and loss of chromosome Y as a single anomaly),
high risk (trisomy 8 alone or with one additional abnor-
mality, abnormalities of chromosome 7 alone or with one
additional abnormality and complex karyotype), and
intermediate risk (all other single or double abnormalities),
with clearly different probabilities of survival in univariate
and multivariate analyses. Patients in the high risk cytoge-
netic subgroup also had a significantly higher risk of AML
evolution in univariate, but not multivariate, analyses.
The frequency of abnormal karyotype and specific chro-
mosomal abnormalities in series of patients with chronic
myelomonocytic leukemia has varied greatly, largely
because of small numbers, inclusion criteria (WHO or FAB
criteria), and referral patterns. Overall, the incidence of
chromosomal abnormalities is close to 25% (range 11-
42%; 27% in the current study) and the karyotypic aber-
rations encountered are not specific for chronic
myelomonocytic leukemia and are commonly found in
other myelodysplastic syndrome subtypes and acute
myeloid leukemia.7,9-13 The most frequently reported chro-
mosomal abnormalities in patients with chronic
myelomonocytic leukemia are trisomy 8, complex kary-
otype, and abnormalities of chromosome 7. 7,9,10 Other less
frequent aberrations include del(12p)11, del(20q)12, and
hypodiploid karyotype13. Although trisomy 8, abnormali-
ties of chromosome 7, and complex karyotype along with
isolated loss of Y chromosome were also the most preva-
lent chromosomal abnormalities in our study, the frequen-
cy of abnormalities of chromosome 7 and complex kary-
otype was lower than in other reports. The lower frequen-
cy of chromosome 7 anomalies and complex karyotypes
in the current study might be due to two different reasons.
First, we used WHO criteria for chronic myelomonocytic
leukemia definition and excluded patients with 20-30%
blasts in bone marrow, in whom the incidence of those
chromosomal abnormalities may be higher. Second, in
contrast to other studies,7,10,14-16 karyotyping was assessed
at diagnosis. Not unexpectedly, and as occurs in other
MDS subtypes,11,12 the current study showed for the first
time that the presence of chromosomal abnormalities is
more common in patients with CMML-2 WHO subtype,
which is characterized by 5-19% blasts (including
promonocytes) in blood or 10-19% in the marrow, or
when Auer rods are present irrespective of the blast plus
promonocyte count.10 Our study also found a higher inci-
dence of chromosomal abnormalities in patients with
more frequent morphological findings of dyserythro-
poiesis and dysgranulopoiesis, which could suggest a
potential relationship between chromosomal aberrations
and the presence of myelodysplastic features. These find-
ings need confirmation in other series.
The natural course of chronic myelomonocytic
leukemia is highly variable, with reported life expectancy
ranging from months to several years. In a meta-analysis
of reported series of chronic myelomonocytic leukemia
median survival was 20 months, ranging from seven to 60
months.10 In the current series median survival was 35
months. Reasons for this longer median survival are
unclear. Although it could just be explained by the hetero-
geneity of the disorder, it might also be partly due to an
inadvertent selection bias, with cytogenetic analysis being
performed and yielding successful results more frequently
in patients with a better prognosis (data not shown). The
wide variation in the clinical course of patients with
chronic myelomonocytic leukemia has provided the stim-
ulus for investigation into factors predictive of outcome. 
The only published study that had previously evaluated
the potential impact of cytogenetic results in chronic
myelomonocytic leukemia showed shorter survival in
patients with chromosomal abnormalities, but was unable
to confirm by multivariate analysis the independent prog-
nostic impact of this finding on outcome.7 Furthermore,
the small number of patients with specific chromosomal
aberrations made it impossible to identify a subpopulation
of patients with unfavorable karyotypes among the abnor-
mal karyotype group.7 Our study, performed in a cohort of
CMML patients who homogenously received supportive
treatment and were considered censored for statistical
analysis at the moment they switched to intensive thera-
py, confirmed the strong association between abnormal
karyotype and shorter survival, and showed a trend for a
greater risk of evolution to acute myeloid leukemia.
Additionally, in the current study, patients with trisomy 8
and with complex karyotype had a very poor outcome
and could be included in the high risk cytogenetic sub-
group. In contrast, patients with normal karyotype or iso-
lated loss of Y chromosome had better survival and were
stratified in the low risk cytogenetic category. As reported
elsewhere,7 patients with abnormalities of chromosome 7
experienced a short survival and a high risk of AML evo-
lution. These results are in line with the universally
accepted poor outcome of abnormalities of chromosome 7
(monosomy 7/del(7q)) in other myeloid malignancies.3,9,15,18
For these reasons and despite their low number in the cur-
rent series, patients with abnormalities of chromosome 7
were included in the high risk category of the new
CMML-specific cytogenetic classification system. The
small number of patients with other specific chromosomal
abnormalities precluded a meaningful analysis of their
potential association with survival or evolution to acute
myeloid leukemia. Therefore, all these chromosomal aber-
rations were merged in a miscellaneous intermediate risk
cytogenetic group.
As discussed above, this new CMML-specific cytoge-
netic risk classification showed a clear and independent
association with survival length. Further, patients in the
high risk cytogenetic category also showed a greater prob-
ability of developing acute myeloid leukemia on univari-
ate analysis. Our data suggest that the prognostic impact
of cytogenetic findings in patients with chronic
myelomonocytic leukemia seems to diverge from that
observed in patients with other MDS subtypes. In contrast
to IPSS, where trisomy 8 is considered among the interme-
diate risk cytogenetic abnormalities, that aberration was
included in the high risk cytogenetic category of the new
CMML-specific cytogenetic risk classification.
Furthermore, isolated del(5q) and del(20q), that are includ-
ed in the low risk IPSS cytogenetic category, were assigned
to the intermediate risk category of the new CMML-spe-
cific cytogenetic risk classification.  We were able to show
that the new CMML-specific cytogenetic classification
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system developed in the present study was more accurate
than the IPSS cytogenetic risk classification for assessing
the prognosis of patients with chronic myelomonocytic
leukemia, most likely due to the grim outcome of patients
with trisomy 8. The advantage of the CMML-specific
cytogenetic risk classification was especially evident for
predicting survival of patients with CMML-MP, a subset
of CMML patients excluded from the original IPSS score.
Nonetheless, it should be underlined that all these findings
require validation in an independent cohort of CMML
patients.
None of the published scoring systems specifically
designed for evaluating prognosis in patients with chronic
myelomonocytic leukemia has included the cytogenetic
results.7,10,17,19 Our data suggest that the present CMML-
specific cytogenetic risk classification could add significant
prognostic information to that provided by other univer-
sally accepted prognostic variables in patients with chron-
ic myelomonocytic leukemia. In accordance with previous
series, our study also confirmed the independent prognos-
tic value of the proportion of blasts in bone marrow,7,10,11,17,19
leukocyte count,17 hemoglobin level,7,10,11 and platelet
count.10,11 Our current understanding of the molecular
bases of chronic myelomonocytic leukemia and other
myeloid neoplasms is evolving very quickly.20,21 In a recent
paper, Kosmider et al. have elegantly shown that TET-2
gene mutations were present at diagnosis in 40% of
patients with chronic myelomonocytic leukemia.22
Furthermore, in this study there was a trend towards
shorter survival for mutated cases, which was statistically
significant for 29 patients with CMML-1 WHO subtype.
Thus, studies of prognostic factors incorporating clinical
parameters, cytogenetic findings, and new molecular
markers are critical to further advance our knowledge of
chronic myelomonocytic leukemia.  
To sum up, this study demonstrates the prognostic rele-
vance of chromosomal abnormalities in patients with
chronic myelomonocytic leukemia and proposes a new
CMML-specific cytogenetic risk classification. Further
studies including a substantial number of patients will be
required to validate and potentially refine this cytogenetic
risk classification before it can be used as a prognostic tool
in the clinical management of patients with chronic
myelomonocytic leukemia. In this sense, a large, multina-
tional, cooperative effort would be essential. The primary
aim of such a study should be to better define the progno-
sis of the different low-incidence specific chromosomal
abnormalities, included in this study in the miscellaneous
intermediate risk cytogenetic group.
Appendix
The following institutions and clinicians participated in the
study: Hospital Universitario La Fe, Valencia: E. Such, J.
Cervera, ML. Senent, and G. Sanz; Hospital Clinic, Barcelona:
D. Costa and B. Nomdedeu; Hospital del Mar, Barcelona: F.
Solé and M. Mallo; Hospital Universitario Vall D’Hebron,
Barcelona: T. Vallespí; Hospital Central de Asturias, Oviedo: E.
Luño; Hospital General de Valencia: R. Collado; Universidad
de Navarra, Pamplona: MJ. Calasanz; Centro Nacional de
Investigaciones Oncológicas, Madrid: J. Cruz and S. Alvarez;
Hospital Txagorritxu; Vitoria: Ardanaz MT; Complejo
Hospitalario, León: F. Ramos; Hospital Clínico Universitario,
Valencia: M. Tormo; Hospital Arnau de Villanova, Valencia: R.
Sancho-Tello; Hospital Universitario de Salamanca: JM
Hernandez-Rivas and C. del Cañizo; Hospital La Princesa,
Madrid: V. Gómez; Hospital Arnau de Vilanova, Lleida: V.
Marco; Hospital Germans Trias i Pujol, Badalona: B. Xicoy;
Hospital de la Ribera, Valencia: S. Bonanad; Hospital Dr.
Peset, Valencia: R. Andreu; Hospital Severo Ochoa; Madrid:
MJ Requena; ICO - D y R, Barcelona: Instituto Catalán de
Oncología Durant y Reinals: R. Duarte.  Hospital Carlos Haya,
Málaga: A. Bailén; Hospital de Sagunto, Valencia: MJ. Arilla;
Hospital. Morales Meseguer, Murcia: M.L. Amigo and F.
Ortuño; Fundación Hospital de Alcorcón, Madrid: L. Villalón;
Hospital. Clínico San Carlos, Madrid: A. Villegas; Hospital
Universitario La Paz, Madrid: R. de Paz; Hospital General de
Castellón: G.Cañigral.
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